X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VP01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The study is a phase II, multi-center, open-label, single-arm trial investigating the safety, effect on lung function and pharmacokinetics of C21 in 60 subjects with IPF.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VP01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Fresh human IPF lung tissue harvested from a patient during lung transplantation showed stable expression of the VP01 target, AT2R, and treatment with clinically relevant concentrations of VP01 caused a dose-dependent decrease of TGFb1.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
